Literature DB >> 20573035

Filaggrin gene variants and atopic diseases in early childhood assessed longitudinally from birth.

Klaus Bønnelykke1, Christian B Pipper, Roger Tavendale, Colin N A Palmer, Hans Bisgaard.   

Abstract

Copenhagen Prospective Study on Asthma in Childhood (COPSAC) was one of the discovery cohorts of the association between eczema and variants in the filaggrin coding gene (FLG). Here, we study the FLG-associated risk of asthma symptoms in early life and describe the temporal relationship in the development of the different FLG-associated atopic outcomes: asthma, sensitization and eczema, assessed longitudinally from birth. A high-risk cohort of 411 children was assessed in a prospective clinical study from birth to school-age. Asthma, acute severe asthma exacerbations, sensitization and eczema were diagnosed prospectively by the investigators. FLG variants R501X and Del4 were determined in 382 Caucasians. Filaggrin variants increased risk of developing recurrent wheeze, asthma and asthma exacerbations (hazard ratio 1.82 [1.06-3.12], p = 0.03), which was expressed within the first 1.5 yr of life. Children with filaggrin variants had a marked and persistent increase in acute severe asthma exacerbations from 1 yr of age (incidence ratio 2.40 [1.19-4.81], p = 0.01) and increased risk of asthma by age 5 (odds ratio 2.62 [1.12-6.11], p = 0.03). FLG variants increased the risk of eczema, manifesting fully in the first year of life (point prevalence ratio for age 0-5 was 1.75 [1.29-2.37]; p-value = 0.0003) contrasting the increased risk of specific sensitization by age 4 (odds ratio 3.52 [1.72-7.25], p = 0.0007) but not age 1.5. This study describes a FLG-associated pattern of atopic diseases characterized by the early onset of asthma symptoms and eczema and later development of sensitization. The association of filaggrin variants with asthma suggests skin barrier dysfunction as a novel, and potentially modifiable, mechanism driving early childhood asthma. (c) 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573035     DOI: 10.1111/j.1399-3038.2010.01073.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  12 in total

1.  Filaggrin mutations increase allergic airway disease in childhood and adolescence through interactions with eczema and aeroallergen sensitization.

Authors:  Adrian Chan; William Terry; Hongmei Zhang; Wilfried Karmaus; Susan Ewart; John W Holloway; Graham Roberts; Ramesh Kurukulaaratchy; Syed Hasan Arshad
Journal:  Clin Exp Allergy       Date:  2018-02       Impact factor: 5.018

2.  Genetic, Clinical, and Environmental Factors Associated With Persistent Atopic Dermatitis in Childhood.

Authors:  Sunna Thorsteinsdottir; Jakob Stokholm; Jacob P Thyssen; Sarah Nørgaard; Jonathan Thorsen; Bo L Chawes; Klaus Bønnelykke; Johannes Waage; Hans Bisgaard
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

3.  The prevalence of atopic dermatitis, asthma, and allergic rhinitis and the comorbidity of allergic diseases in children.

Authors:  Soyoung Hong; Dong Koog Son; Wan Ryung Lim; Sun Hang Kim; Hyunjung Kim; Hye Yung Yum; Hojang Kwon
Journal:  Environ Health Toxicol       Date:  2012-02-13

Review 4.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.

Authors:  Mark Boguniewicz; Donald Y M Leung
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

5.  Clinical presentation of atopic dermatitis by filaggrin gene mutation status during the first 7 years of life in a prospective cohort study.

Authors:  Charlotte Giwercman Carson; Morten Arendt Rasmussen; Jacob P Thyssen; Torkil Menné; Hans Bisgaard
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

6.  Filaggrin gene defects are independent risk factors for atopic asthma in a Polish population: a study in ECAP cohort.

Authors:  Joanna Ponińska; Bolesław Samoliński; Aneta Tomaszewska; Filip Raciborski; Piotr Samel-Kowalik; Artur Walkiewicz; Agnieszka Lipiec; Barbara Piekarska; Jarosław Komorowski; Edyta Krzych-Fałta; Andrzej Namysłowski; Jacek Borowicz; Grażyna Kostrzewa; Sławomir Majewski; Rafał Płoski
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional study.

Authors:  Jacob P Thyssen; Allan Linneberg; Berit C Carlsen; Jeanne D Johansen; Kåre Engkilde; Torben Hansen; Flemming Pociot; Oluf Pedersen; Michael Meldgaard; Pal B Szecsi; Steen Stender; Torkil Menné
Journal:  BMJ Open       Date:  2011-03-15       Impact factor: 2.692

8.  Interplay of filaggrin loss-of-function variants, allergic sensitization, and eczema in a longitudinal study covering infancy to 18 years of age.

Authors:  Ali H Ziyab; Wilfried Karmaus; Mitra Yousefi; Susan Ewart; Eric Schauberger; John W Holloway; Hongmei Zhang; Syed Hasan Arshad
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

9.  Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review.

Authors:  Maria J Martin; Miguel Estravís; Asunción García-Sánchez; Ignacio Dávila; María Isidoro-García; Catalina Sanz
Journal:  Genes (Basel)       Date:  2020-04-18       Impact factor: 4.096

10.  Mutations in the Filaggrin are Predisposing Factor in Korean Children With Atopic Dermatitis.

Authors:  Ho-Sung Yu; Mi-Jin Kang; Young-Ho Jung; Hyung-Young Kim; Ju-Hee Seo; Young-Joon Kim; Seung-Hwa Lee; Ha-Jung Kim; Ji-Won Kwon; Byoung-Ju Kim; Jinho Yu; Soo-Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2013-03-20       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.